UNDERSTANDING IEI:





GICE

Thursday 22-Friday 23 January 2026, 9:30-17:45 GMT

Thursday 22 January

9:00-9:30	Registration for those attending in person Research, 20c Guilford Street, London, WC1	(Ryan Connolly Room, Zayed Centre for N 1DZ). Those joining online to log in at 9:28
9:30-13:30	Session 1: HLH	
9:30-9:50	Pathophysiology and new classification of HLH	Anupama Rao, Consultant in Paediatric Haematology, GOSH, UK
9:50-10:10	In-depth understanding of Rab-27 immune defect	Maaike Kusters, Consultant in Paediatric Immunology, GOSH, UK
10:10-10:30	Inflammasomopathy in monogenic HLH	Elizabeth Rivers, Consultant in Paediatric Immunology, GOSH, UK
10:30-10:50	Diagnostics for monogenic HLH	Kimberly Gilmour, Director of Immunology Laboratory services, GOSH, UK
10:50-11:00	Q&A	
11:00-11:30	Break	
11:30-12:00	HLH-2004: Diagnostics and treatment revisited	Jan-Ing Henter, Professor of Clinical Paediatric Oncology, Karolinska University Hospital, Sweden
12:00-12:30	Alemtuzumab as first line therapy for monogenic HLH	Despina Moshous, Consultant in Paediatric Immunology, Necker-Enfants Malades University Hospital, France
12:30-13:00	Targeting HLH with biologics: what is working? and what is next?	Reem Elfeky, Consultant in Paediatric Immunology, GOSH, UK
13:00-13:30	Q&A	
13:30-14:30	Lunch break	
14:30-17:30	Session 2: DADA2	
14:30-15:00	Linking pathophysiology and clinical presentation of DADA2 to the development of novel therapies	Despina Eleftheriou , Consultant in Paediatric rheumatology, GOSH; Professor of Paediatric rheumatology, UCL GOS ICH, UK
15:00-15:30	Etanercept for DADA2: Firefighter or bridge for HSCT	Isabelle Meyts, Consultant in Paediatric Haemato-oncology, University Ziekenhuis Leuven, Belgium
15:30-16:00	Gene therapy in DADA2: are we close?	Federica Barzaghi, Consultant in Paediatric Immunology, Immunohaematology Unit, San Raffaele Hospital, Italy
16:00-16:10	ADA2 enzyme assay and utility for confirming VUSes and monitoring engraftment post HSCT	Mark Davis, Healthcare Scientist - Immunology, GOSH, UK
16:10-16:30	Q&A	
16:30-17:00	Break	
17:00-17:30	Interactive case presentations	
17:30	End of day 1	

UNDERSTANDING IEI:



LINKING PATHOPHYSIOLOGY WITH EVOLVING THERAPEUTIC STRATEGIES

EZID

Friday 23 January

9:15-9:30	Arrival for those attending in person (Ryan Guilford Street, London, WC1N 1DZ). Those jo	Connolly Room, Zayed Centre for Research, 20c
9:30-13:30	Session 3: IEI with Immune dysregulation	
9:30-10:00	Therapeutic intervention for Gain- and Loss- of-function STAT1 mutations	Catharina Schütz, Professor of Paediatric Immunology in University Hospital Carl Gustav Carus Technische Universität Dresden, Germany
10:00-10:30	Comparative study Sirolimus versus Leniolisib in APDS1 and APDS2	Beatrice Rivalta, Paediatric Immunologist, Department of Clinical Immunology and Vaccinology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy
10:30-11:00	Position of Abatacept as targeted therapy for CTLA4 and LRBA defects	Safa Baris, Professor in Paediatric Immunology, Marmara University Medical Faculty, Turkey
11:00-11:30	Q&A	
11:30-12:00	Break	
12:00-12:30	Gene therapy in IPEX: Opening new doors	Rosa Bacchetta, Professor (Research) of Paediatrics (Stem Cell Transplantation), Standford University School of Medicine, USA
12:30-13:00	Pharmacist role in the era of personalised medicine- opportunities and challenges	Fan Ing Cheng, Senior clinical pharmacist in Immunology, GOSH, UK
13:00-13:30	Q&A	
13:30-14:30	Lunch break	
14:30-17:30	Session 4: Secondary immunodeficiency	
		O T. I O (A. I.(I.
14:30-15:00	Is it CVID or secondary immunodeficiency- how can you tell?	Susan Tadros, Consultant in Adult Immunology, Royal Free London, UK
14:30-15:00 15:00-15:30		
	how can you tell? Biological therapies and immunosuppression: A guide to risk mitigation and management	Royal Free London, UK David Lowe, Consultant in Adult Immunology,
15:00-15:30	how can you tell? Biological therapies and immunosuppression: A guide to risk mitigation and management approach Interactive case presentation and	Royal Free London, UK David Lowe, Consultant in Adult Immunology,
15:00-15:30 15:30-16:00	how can you tell? Biological therapies and immunosuppression: A guide to risk mitigation and management approach Interactive case presentation and pharmaceutical symposium	Royal Free London, UK David Lowe, Consultant in Adult Immunology,
15:00-15:30 15:30-16:00 16:00-16:30	how can you tell? Biological therapies and immunosuppression: A guide to risk mitigation and management approach Interactive case presentation and pharmaceutical symposium Break	Royal Free London, UK David Lowe, Consultant in Adult Immunology, Royal Free London, UK Mercedes Selby, Senior Biomedical Scientist, GOSH, UK
15:00-15:30 15:30-16:00 16:00-16:30 16:30-18:00	how can you tell? Biological therapies and immunosuppression: A guide to risk mitigation and management approach Interactive case presentation and pharmaceutical symposium Break Session 5: Laboratory diagnostics Interferon stimulated gene assay for	Royal Free London, UK David Lowe, Consultant in Adult Immunology, Royal Free London, UK Mercedes Selby, Senior Biomedical Scientist, GOSH, UK Arnold Awuah, Clinical Scientist Trainee in Immunology, GOSH, UK
15:00-15:30 15:30-16:00 16:00-16:30 16:30-18:00 16:30-16:45	how can you tell? Biological therapies and immunosuppression: A guide to risk mitigation and management approach Interactive case presentation and pharmaceutical symposium Break Session 5: Laboratory diagnostics Interferon stimulated gene assay for diagnosing and monitoring interferonopathies	Royal Free London, UK David Lowe, Consultant in Adult Immunology, Royal Free London, UK Mercedes Selby, Senior Biomedical Scientist, GOSH, UK Arnold Awuah, Clinical Scientist Trainee in
15:00-15:30 15:30-16:00 16:00-16:30 16:30-18:00 16:30-16:45 16:45-17:00	how can you tell? Biological therapies and immunosuppression: A guide to risk mitigation and management approach Interactive case presentation and pharmaceutical symposium Break Session 5: Laboratory diagnostics Interferon stimulated gene assay for diagnosing and monitoring interferonopathies Cytokines and access to targeted therapy	Royal Free London, UK David Lowe, Consultant in Adult Immunology, Royal Free London, UK Mercedes Selby, Senior Biomedical Scientist, GOSH, UK Arnold Awuah, Clinical Scientist Trainee in Immunology, GOSH, UK Micol Ferro, Senior Healthcare Scientist and
15:00-15:30 15:30-16:00 16:00-16:30 16:30-18:00 16:30-16:45 16:45-17:00 17:00-17:15	how can you tell? Biological therapies and immunosuppression: A guide to risk mitigation and management approach Interactive case presentation and pharmaceutical symposium Break Session 5: Laboratory diagnostics Interferon stimulated gene assay for diagnosing and monitoring interferonopathies Cytokines and access to targeted therapy Advances in phosphorylation assays Th17 as a biomarker for immune	Royal Free London, UK David Lowe, Consultant in Adult Immunology, Royal Free London, UK Mercedes Selby, Senior Biomedical Scientist, GOSH, UK Arnold Awuah, Clinical Scientist Trainee in Immunology, GOSH, UK Micol Ferro, Senior Healthcare Scientist and Clinical Scientist, GOSH, UK Annabelle Lea Mai, Laboratory Manager,

Endorsed by:

